The Effects of Multi-Donor Fecal Microbiota Transplantation Capsules Combined with Thalidomide on Hormone-Dependent Ulcerative Colitis

Figures & data

Table 1 Evaluation of Clinical Efficacy at Week 13 of Treatment in the Two Groups

Group	Number of Cases (No.)	Overall Response Rate(%)	Clinical Response (%)	Mucosal Healing (%)	Clinical Non-Response (%)
FMT+S	30	22(73.33)	12(40.00)	10(33.33)	8(26.67)
FMT	29	12(41.38)	6(20.69)	6(20.69)	17(58.62)

Abbreviations: FMT, fecal microbiota transplants; S, thalidomide.

Table 2 Mayo Score Changes at Different Time Nodes in Two Groups

Time Node	Before Treatment	Week 1 After Treatment	Week 13 After Treatment
FMT±S	13.28±3.23	10.57±2.99*	6.35±1.57**
FMT	13.66±3.39	11.56±3.38*	9.96±2.09*
χ^2/t	0.189	0.554	12.904
p	0.967	0.656	0.044

Notes: Comparison of modified Mayo scores in each group before treatment;*P<0.05 indicated statistical differences, and **P indicates significant statistical differences.

Abbreviations: FMT, fecal microbiota transplants; S, thalidomide.

Table 3 Baseline Changes of Indicators in Both Groups at Week 13, Compared with Those Before Treatment

Indicator	Fecal Calprotectin
	Baseline	Week 1	Week 13
FMT+S	288.35(122.15,339.13)	222.87(101.88,279.87)	143.00(92.09,199.65)
FMT	265.89(128.68,339.89)	227.19(109.93,288.80)	198.22(115.37,224.38)
χ2/t	0.677	0.908	2.556
p	0.567	0.444	0.046
Indicator	C-reactive protein
	Baseline	Week 1	Week 13
FMT+S	29.77(22.39,49.37)	16.28(12.89,29.87)	12.76(10.80,20.32)
FMT	28.39(18.62,49.77)	17.99(13.24,28.02)	15.27(10.37,24.20)
χ2/t	0.322	0.098	1.356
p	0.832	0.465	0.031

Abbreviations: FMT, fecal microbiota transplants; S, thalidomide.